Urolithin A has one of the more interesting stories in the longevity supplement world. It connects the gut microbiome, foods such as pomegranates and walnuts, mitochondrial recycling and age-related muscle decline. Unlike many supplements built almost entirely on animal research, urolithin A has been tested in several randomized human trials.
That still does not make it a proven longevity treatment. The human studies are relatively small and short, several important outcomes have been inconsistent, and much of the research has commercial involvement. The evidence is promising enough to examine—but not strong enough to treat the supplement as essential.
What is urolithin A?
Urolithin A is a metabolite produced when certain gut bacteria process ellagitannins and ellagic acid. These compounds occur in foods including pomegranates, walnuts and some berries.
Not everyone produces the same amount. Gut-microbiome differences mean that two people can eat similar foods and generate very different urolithin levels. Supplemental urolithin A bypasses that conversion step by providing the finished compound directly.
Why mitochondria matter
Mitochondria help cells convert nutrients into usable energy. They are dynamic structures that become damaged, divide, fuse and are recycled. The selective removal of damaged mitochondria is called mitophagy.
Mitophagy is essential biology, and impaired mitochondrial quality control is associated with aging and disease. In laboratory and animal models, urolithin A activates pathways connected with mitophagy and improves certain measures of muscle function.
What have human trials found?
Older adults: endurance improved, but the primary walking outcome did not
A randomized, double-blind trial published in JAMA Network Open studied 66 adults ages 65 to 90. Participants received 1,000 mg of urolithin A or placebo daily for four months.
The supplement group improved endurance during repeated hand and leg muscle contractions and showed changes in several biomarkers associated with mitochondrial metabolism. However, the study did not find a statistically significant benefit for its primary functional outcome, six-minute walking distance, compared with placebo. Maximal ATP production in hand muscle also did not significantly differ between groups.
Middle-aged adults: encouraging secondary results
Another randomized trial tested 500 mg and 1,000 mg daily for four months in sedentary, overweight middle-aged adults. Researchers reported improvements in some strength, exercise-performance and mitochondrial measures. The prespecified primary outcome—peak power output—did not significantly improve.
This pattern is important. Positive secondary outcomes can identify a real biological effect, but they do not carry the same weight as consistently meeting a study’s primary endpoint.
The latest pooled assessment remains cautious
A 2026 systematic review and meta-analysis of randomized trials found that the pooled improvement in six-minute walk distance was not statistically significant. Other outcomes were too different across studies to combine reliably and were described as exploratory rather than reproducible effects.
| Claim | Current human evidence |
|---|---|
| Activates mitochondrial pathways | Supported by biomarker and gene-expression changes in small trials |
| Improves muscle endurance | Promising findings in some trials |
| Improves strength or walking performance | Mixed; some positive secondary results, inconsistent primary outcomes |
| Prevents sarcopenia | Not established |
| Extends human lifespan | Not demonstrated |
What about immune aging?
A more recent randomized trial studied four weeks of urolithin A in older adults and examined age-related immune changes. Researchers reported shifts in immune-cell mitochondrial activity and exploratory molecular signals. This expands the research story, but it is not evidence that the supplement prevents infections, autoimmune disease or other clinical outcomes.
Can you get it from food?
Pomegranates, walnuts and berries offer fiber, polyphenols and other nutrients whether or not your microbiome produces substantial urolithin A. Eating these foods is not equivalent to taking a standardized dose of the finished metabolite, but that does not make the foods inferior. They deliver broader nutritional benefits that an isolated supplement cannot reproduce.
If the only goal is maximizing blood levels of urolithin A, a standardized supplement is more predictable. If the goal is overall health, food quality still deserves priority.
Dosage used in studies
Human trials have commonly evaluated daily doses of 500 mg or 1,000 mg, usually for one to four months. Those are research doses, not proof that everyone should take that amount indefinitely.
There is no established dose for extending lifespan because lifespan extension has not been demonstrated. Product labels should not be treated as personalized medical advice.
Safety and limitations
Urolithin A was generally well tolerated in the published short-term trials, with no major safety signal attributed to the supplement in the studied populations. That is reassuring but limited. Small trials lasting a few months cannot establish safety across years or in every medical condition.
People who are pregnant or breastfeeding, taking multiple medications, receiving cancer treatment, living with significant kidney or liver disease or managing a serious medical condition should discuss concentrated supplements with a qualified clinician.
Follow the research funding
Several key urolithin A trials were funded by, included employees of or otherwise involved the company developing the branded ingredient used in the research. Industry funding does not invalidate a study. Randomization, blinding and peer review still matter.
It does increase the need for independent replication, larger samples, longer follow-up and clinically meaningful outcomes—not only proprietary biomarkers or secondary endpoints.
Who might reasonably consider it?
- An adult who already strength trains, eats adequately and wants to experiment with an evidence-aware mitochondrial supplement
- An older adult interested in muscle endurance who understands that benefits may be modest or absent
- Someone willing to define a measurable outcome before spending money
- A person whose clinician sees no meaningful interaction or medical concern
Who should probably spend elsewhere first?
- Someone not performing resistance or aerobic exercise
- Anyone consistently undersleeping or eating inadequate protein
- A person expecting the supplement to reverse aging or build visible muscle by itself
- Someone whose budget would be better used for nutritious food, preventive care or a well-designed training program
A practical self-test
If you decide to use urolithin A, avoid judging it by a vague feeling of “cellular energy.” Select outcomes you can repeat:
- Record your training program, sleep and diet before starting.
- Choose one or two benchmarks, such as repetitions at a fixed resistance or a repeatable aerobic test.
- Keep the rest of the program reasonably stable.
- Reassess after a defined period rather than taking it indefinitely by default.
- Stop for side effects and discuss concerning symptoms with a clinician.
This cannot prove what the supplement did, but it is more informative than relying on marketing language or the expectation that an expensive capsule must be working.
The Biohack Journey verdict
Urolithin A is scientifically plausible and has more human research than many compounds sold for mitochondrial health. Trials suggest biological activity and possible benefits for certain measures of muscle endurance.
The results are not yet strong or consistent enough to call it a proven muscle-building, disease-preventing or life-extending supplement. Consider it an optional experiment built on top of exercise, protein, sleep and medical care—not a replacement for any of them.
Sources
- Randomized trial: muscle endurance and mitochondrial health in older adults
- Randomized trial: strength, exercise performance and mitochondrial biomarkers in middle-aged adults
- First-in-human study: safety and mitochondrial molecular signatures
- Systematic review: targeting aging with urolithin A
- 2026 systematic review and meta-analysis of randomized muscle-health trials
- Randomized trial: urolithin A and age-related immune decline
Educational information only. This article does not diagnose, treat or prevent disease and does not replace individualized advice from a qualified healthcare professional.